Loading organizations...
Metabiota is a technology company.
Metabiota develops systems for infectious disease preparedness. It strengthens surveillance capabilities for local health agencies through public health workforce training and laboratory infrastructure for human and animal health. This work builds resilience, aiming to mitigate future outbreaks.
Founded in 2008 by Nathan Wolfe, Metabiota emerged from the insight that proactive strategies counter global pandemics. Wolfe, a virologist-ecologist, envisioned an organization for early identification and analysis of infectious disease risks, leveraging data science and field expertise for predictive models and response.
Metabiota serves local health agencies and international public health bodies, equipping them with tools for rapid disease detection and intervention. Acquired by the Cameroon-based nonprofit Health and Development in Action (HEADA) in 2022, the company continues its mission to bolster global capacity in preventing and managing outbreaks, fostering a more resilient global health framework.
Metabiota has raised $34.0M across 2 funding rounds.
Metabiota has raised $34.0M in total across 2 funding rounds.
Metabiota has raised $34.0M in total across 2 funding rounds.
Metabiota's investors include John DeLoche, Bain Capital Ventures, Bowery Capital, DCVC (Data Collective), Flex Capital, Great Oaks Venture Capital, Khosla Ventures, Obvious Ventures, Dennis Crowley, Jim Pallotta, Mike Kourey, Roger Ehrenberg.
Metabiota is a technology company founded in 2008 that builds data analytics platforms to predict and assess infectious disease threats by compiling global microbial data.[1][2][3] It serves governments, insurance companies, health organizations, and livestock producers, solving the problem of detecting and preventing disease outbreaks through surveillance, workforce training, and laboratory infrastructure.[1][2][4] The company demonstrated early capabilities in mapping SARS-CoV-2 spread and partnered with insurers like Marsh and Munich Re for outbreak coverage products, while USAID collaborations like PREDICT highlighted its role in proactive epidemic response.[2] Acquired by the Cameroon-based nonprofit Health and Development in Action (HEADA) in 2022, Metabiota shifted toward strengthening local health agency capacities, though its growth momentum appears tempered post-acquisition with a focus on public health training rather than commercial expansion.[4]
Metabiota was founded in 2008 by Nathan Wolfe, a virologist, as the commercial arm of his research project on global pathogen surveillance.[2][6] Headquartered in San Francisco with 51-200 employees at its peak, it emerged from Wolfe's efforts to digitize microbial data and predict outbreaks, gaining early traction through partnerships like USAID's PREDICT and PREVENT programs.[2][5] Pivotal moments included staff support during the 2014 Western African Ebola epidemic in Sierra Leone's Kenema labs—despite criticism from Médecins Sans Frontières for data-sharing limitations—and independent demonstrations of analytics during the early SARS-CoV-2 outbreak alongside BlueDot.[2] Investments from Google ($1 million) and others like Rosemont Seneca Technology Partners fueled growth, but geopolitical scrutiny arose from its Ukraine lab work amid Russia's 2022 bioweapons claims.[2] Leadership includes CEO Nita Madhav and Chief Scientific Officer Edward Rubin.[2]
Metabiota rides the wave of epidemic intelligence tech, leveraging AI and big data for biosecurity amid rising pandemics like COVID-19 and potential zoonotic threats.[2][3] Its timing aligned with post-Ebola investments in prediction tools, influencing the ecosystem by pioneering data-driven insurance and public-private partnerships that scaled to global players like USAID and Google.[1][2] Market forces favoring it include escalating climate-driven outbreaks and demand for proactive surveillance, positioning it as a bridge between tech analytics and public health infrastructure in underserved regions.[4][5] By training workforces and building labs, it amplifies local ecosystems, though the 2022 HEADA acquisition reflects a trend toward nonprofit integration in global health tech.[4]
Post-acquisition, Metabiota will likely deepen nonprofit-led expansions in Africa and beyond, focusing on surveillance training amid trends like AI-enhanced pathogen detection and climate-resilient health systems.[3][4] Evolving biosecurity regulations and post-COVID funding could boost its influence, potentially reviving commercial arms for insurance analytics. As threats intensify, its foundational data expertise positions it to shape resilient global health networks, tying back to its core mission of digitizing microbial threats for prevention.[1][2]
Metabiota has raised $34.0M across 2 funding rounds. Most recently, it raised $31.0M Series A in May 2015.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 28, 2016 | Ancera | $8.9M Series A | — | Carl R. Zwerner, Robert Mann, Packers Sanitation Services |